CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing its leading drug candidate, Berubicin, to move forward with clinical trials in Poland. This move comes after sub-licensee WPD Pharmaceuticals Inc. has identified a contract research organization … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), Sub-Licensee Partner Advancing Lead Drug Candidate in First-Ever Phase 1 and Phase 2 Clinical Trials”
Investment Considerations CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP)”
Poland trials will include the first ever Phase 1 trial for pediatric patients suffering from glioblastoma multiforme CNS Pharmaceuticals has made significant strides in its Berubicin manufacturing process due to its dual-track approach and expects to begin production of its drug candidate at Pharmaceuticals International during the third quarter of 2020 The Company’s CFO recently … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Sub-Licensee Partner Announces CRO for Phase 1 and Phase 2 Berubicin Trials in Poland”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, announced it will be one of the companies appearing at this year’s online Oppenheimer Fall Healthcare Life Sciences & MedTech Summit; the event is scheduled for Tuesday, Sept. 2020. The company’s … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Slated to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that CEO John Climaco will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference. According to the update, Climaco’s presentation is scheduled to … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference”
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) develops novel treatments for primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Virtual Coverage of The Wall Street Investor Forum”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has provided updated information on the manufacturing of its lead drug candidate, Berubicin. The company announced it has reached key milestones in the manufacturing process as it has followed a dual-track, … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Progress Report on Critical Steps for Manufacturing of Leading Drug Candidate”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, was featured in an editorial by Financial News Media. The piece, titled “Global Brain Tumor Therapeutics Market Targeted to Reach $3.4 Billion by 2025,” covers CNSP and other biotech … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Editorial Projecting Significant Growth for Global Brain Tumor Therapeutics Sector”
CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, this morning announced the appointment of Patrick Wen, M.D., an accomplished neuro-oncologist, to the company’s Science Advisory Board. “We are excited to add Dr. Wen, a neuro-oncologist with … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Appoints Dr. Patrick Wen to Science Advisory Board”
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently announced its engagement of Worldwide Clinical Trials as the contract research organization (“CRO”) for its upcoming Berubicin clinical trials. Worldwide, which specializes in therapeutic areas where there remain … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Engages Worldwide to Further Drive Berubicin’s Clinical Development”
